论文部分内容阅读
目的:评价ST段抬高型心肌梗死(STEMI)患者置入西罗莫司洗脱支架(SES)与金属裸支架(BMS)的围手术期和手术后中期临床预后的差异。方法:因STEMI接受择期经皮冠状动脉介入治疗(PCI)并置入支架治疗的258例,分为SES组和BMS组。记录患者住院期和随访期内临床资料,比较2组主要不良心脑血管事件(MACCE)的发生率及无事件生存率。结果:2组基线情况、术前术后的用药和随访时间、成功率等均差异无统计学意义。在住院期和随防期内,2组总的MACCE发生率差异无统计学意义,其中死亡、再次心肌梗死、卒中和再次血管重建的发生率也均差异无统计学意义(均P>0.05)。2组随访期内的无事件生存率也差异无统计学意义(89.3%∶87.7%,P>0.05)。结论:STEMI患者PCI时置入SES安全有效,住院期与中期不良事件发生率极低。STEMI置入SES对患者不良事件的长期影响还有待研究。
Objective: To evaluate the perioperative and postoperative metaphase clinical outcomes of patients with STEMI who underwent sirolimus-eluting stent (SES) versus bare metal stent (BMS). Methods: A total of 258 patients with STEMI undergoing percutaneous coronary intervention (PCI) and stent placement were divided into SES group and BMS group. The clinical data of patients during hospitalization and follow-up were recorded. The incidence of MACCE and the event-free survival rate were compared between the two groups. Results: There were no significant differences in baseline, preoperative and postoperative medication, follow-up time and success rate. There was no significant difference in the incidence of MACCE between the two groups during the period of hospitalization and within the period of prevention. There was also no significant difference in the incidence of death, re-MI, stroke and revascularization between the two groups (all P> 0.05) . There was no significant difference in event-free survival between the 2 groups (89.3% vs 87.7%, P> 0.05). CONCLUSIONS: STEMI is safe and effective in patients with SES during PCI, and the incidence of adverse events in hospital and in the medium term is extremely low. The long-term impact of STEMI on SES on patients’ adverse events remains to be studied.